Scholarlink

<p>Paraoxonase 1 (PON1) is a hydrolyzing paraoxon enzyme; it prevents the development of oxidative stress damage. PON1 primarily binds to high-density lipoprotein (HDL). Although PON1 is not directly expressed in the brain, it crosses the blood-brain barrier (BBB) via HDL, potentially exerting neuroprotective effects. It has been shown that the reduction of PON1 activity is associated with the development and progression of Alzheimer’s disease (AD) and other neurodegenerative diseases by inducing oxidative stress and neuroinflammation. Despite these findings, the exact role of PON1 in AD and other neurodegenerative diseases is not fully elucidated. Therefore, the aim of the present review was to discuss and explain the precise role of PON1 in AD, and how PON1 activators could be effective in the management of AD. Clinical trial: not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unveiling the Neuroprotective Effect of Paraoxonase 1 in Neurodegenerative Diseases Focusing on Alzheimer’s Disease

  • 期刊论文

  • 发表日期：

    2025年12月3日

查看全文
  • Alaa Ismail,
  • Hayder M. Al-kuraishy,
  • Ali I. Al-Gareeb,
  • Athanasios Alexiou,
  • Marios Papadakis,
  • Safaa A. Faheem,
  • Gaber El-Saber Batiha

摘要

Paraoxonase 1 (PON1) is a hydrolyzing paraoxon enzyme; it prevents the development of oxidative stress damage. PON1 primarily binds to high-density lipoprotein (HDL). Although PON1 is not directly expressed in the brain, it crosses the blood-brain barrier (BBB) via HDL, potentially exerting neuroprotective effects. It has been shown that the reduction of PON1 activity is associated with the development and progression of Alzheimer’s disease (AD) and other neurodegenerative diseases by inducing oxidative stress and neuroinflammation. Despite these findings, the exact role of PON1 in AD and other neurodegenerative diseases is not fully elucidated. Therefore, the aim of the present review was to discuss and explain the precise role of PON1 in AD, and how PON1 activators could be effective in the management of AD. Clinical trial: not applicable.